Log In
Print
BCIQ
Print
Print this Print this
 

golvatinib (E7050)

  Manage Alerts
Collapse Summary General Information
Company Eisai Co. Ltd.
DescriptionVascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) and c-Met receptor tyrosine kinase inhibitor
Molecular Target Vascular endothelial growth factor (VEGF) receptor 2 (VEGFR-2) (KDR/Flk-1) ; c-Met receptor tyrosine kinase (c-MET) (MET) (HGFR) (c-Met proto-oncogene)
Mechanism of ActionVascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) kinase inhibitor; c-Met receptor tyrosine kinase inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationSolid tumors
Indication DetailsTreat solid tumors
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today